BILLERICA, Mass., Oct. 14, 2012 /PRNewswire/ -- Seahorse Bioscience, the world leader in instruments and assay kits for measuring cell metabolism, unveiled XFe - the world’s most advanced cell metabolism analyzer - at the Society for Neuroscience’s 42nd Annual Meeting, in New Orleans, October 13-17. Booth #3215.
The Seahorse Bioscience XFe Extracellular Flux Analyzer measures the two major energy pathways of the cell - mitochondrial respiration and glycolysis - in a microplate, in real-time. The XFe Analyzer and stress test kits have standardized the measurements of mitochondrial dysfunction and glycolysis, enabling scientists to better understand the connection between physiological traits of cells with genomic and proteomic data. This knowledge is generating new insights into mitochondrial respiration and glycolysis and their impact on new treatments of neurodegenerative diseases.“XF technology plays an important role in our drug development efforts as we explore innovative therapeutics for the under-served needs in neurology,” stated Rebecca Pruss, Ph.D., CSO of Trophos. “XF data is shown in our poster #54.17 that Trophos Senior Scientist, Caroline Gouarne, Ph.D., will present at Neuroscience on Saturday, October 13, 2012 at 1:00 PM. It’s titled Analysis of respiratory defects in primary neurons from BACHD transgenic rats.”
The XFe Analyzer and stress test kits are the Gold Standard platform for metabolic assays in neuroscience. The XFe Analyzer is able to identify mitochondrial dysfunction and subtle changes in neuronal cell metabolism before the development of observable neurodegeneration.
“Our lab’s aim is to identify the role of mitochondrial dysfunction in Alzheimer’s Disease (AD) pathogenesis, with the ultimate goal of developing therapeutics that target mitochondrial bioenergetics for AD prevention and treatment. With the XF Analyzer we were able to demonstrate that mitochondrial bioenergetics deficits are evident in neurons from AD transgenic mice at the embryonic stage,” stated Dr. Roberta Brintonfrom the University of Southern California, Los Angeles, CA. Jia Yao, Ph.D., who works in Dr. Brinton’s lab added,“The XF Analyzer has also enabled us to demonstrate that estrogen, a neuroprotective steroid, differentially potentiates the metabolic function of neurons and glia. With this information we have now expanded our investigation into potential therapeutic candidates for AD prevention and treatment, and the XF96 Analyzer provides the throughput capacity for preclinical screening.”
“Our decision to launch this landmark product at Neuroscience was strategic in that XF technology has already enabled a new focus on metabolic dysfunction as a therapeutic target in Autism, Alzheimer’s, Parkinson’s, traumatic brain injury, diabetes induced cognitive dysfunction, migraines, and neuroprotection,” stated Jay Teich, Founder and CEO of Seahorse Bioscience.
The new XFe Analyzer is designed to enable the scientific community to build a knowledgebase that will turn cell metabolism into a target of new therapies for neurodegenerative disease. The XFe Analyzer sets a universal standard for acquiring and reporting cell metabolism data. It enables cloud-based sharing of the elements and protocols of metabolic experiments, affording new users and experts the opportunity to collaborate and accelerate their research.
About Seahorse Bioscience
Seahorse Bioscience XF Analyzers and stress test kits are the industry standard in cellular bioenergetic measurements. Over 2,500 scientists worldwide are advancing their research in understanding the role of cell metabolism in Neurodegeneration, Aging, Cancer, Cardiovascular, Cell Physiology, Toxicology & Hepatobiology, Immunology, Infectious Diseases, Mitochondrial Diseases, Model Organisms, Obesity, Diabetes, Metabolic Disorders, Screening, and Translational Medicine. Founded in 2001, Seahorse Bioscience is headquartered in Billerica, Massachusetts, U.S., and has regional offices in Copenhagen, Denmark; and Shanghai, China. Learn more about Seahorse Bioscience at www.seahorsebio.com.
About Trophos
Trophos is a late stage clinical stage company with a pipeline of original molecules in development for neurological and cardiac diseases. These diseases include spinal muscular atrophy (SMA), Multiple Sclerosis (MS) disability progression and Cardiac Ischemia-Reperfusion Injury (IRI). Trophos additionally has collaborative research projects in other neurological conditions. Trophos was founded in 1999, and is based in Marseille, France. Learn more about Trophos at www.trophos.com.
About the University of Southern California
The University of Southern California is one of the world’s leading private research universities. An anchor institution in Los Angeles, a global center for arts, technology and international trade, USC enrolls more international students than any other U.S. university and offers extensive opportunities for internships and study abroad. With a strong tradition of integrating liberal and professional education, USC fosters a vibrant culture of public service and encourages students to cross academic as well as geographic boundaries in their pursuit of knowledge.
Press Contact:
Cynthia Egan
Director of Marketing
Seahorse Bioscienc
cegan@seahorsebio.com
978-671-1600
SOURCE Seahorse Bioscience
